Asterias Biotherapeutics Inc (NYSEMKT:AST) was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Wednesday, August 2nd.

Shares of Asterias Biotherapeutics (AST) opened at 3.10 on Wednesday. The stock’s market cap is $152.72 million. The company’s 50-day moving average is $3.45 and its 200-day moving average is $3.41. Asterias Biotherapeutics has a 12-month low of $2.54 and a 12-month high of $5.80.

TRADEMARK VIOLATION WARNING: “ValuEngine Downgrades Asterias Biotherapeutics Inc (NYSEMKT:AST) to Sell” was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another site, it was illegally copied and republished in violation of US and international copyright and trademark legislation. The correct version of this report can be viewed at https://www.thecerbatgem.com/2017/08/16/valuengine-downgrades-asterias-biotherapeutics-inc-nysemktast-to-sell-updated.html.

Asterias Biotherapeutics Company Profile

Asterias Biotherapeutics, Inc is a biotechnology company. The Company is engaged in developing and commercializing therapies in the fields of cell therapy and regenerative medicine. The Company has over two technology platforms. The first is an immunotherapy platform to teach cancer patients’ immune systems to attack their tumors.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Stock Ratings for Asterias Biotherapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Asterias Biotherapeutics Inc and related stocks with our FREE daily email newsletter.